Array BioPharma, Inc. (NASDAQ:ARRY)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Recs

3
Player Avatar redwings103149 (59.17) Submitted: 9/15/2009 11:03:37 PM : Outperform Start Price: $2.84 ARRY Score: -3.27

What a great price to get into this stock. Well little history on arry was that they have had a hugeeee pipeline but have been blessed with some terrible along with a trial 3 data result that did not meet its ends. Away from the bad they have four game changers due within the next 6months so spec alone will hype this baby up eventually.

Report this Post 1 Comment
Member Avatar lonewulf47638 (51.51) Submitted: 11/5/2009 11:01:28 AM
Recs: 0

I have long term options on this one and hope to call at 2.50.

Report this Post

Featured Broker Partners


Advertisement